A eureka consortium of scientists from research institutions and 8 leading plant breeding/biotechnology companies will apply innovative molecular techniques to solve urgent quality problems in the most important european cereals.
Development of anti-cancer vaccines. The technology combines a promising tumour antigen with a powerful vaccine vector to provide a specific immunotherapy.
Acceleration and diversification of flavour formation in semi-hard cheeses, by controlling amino-acid catabolism with lactic acid bacteria (lab).
A novel platform for the sustained intracellular delivery of therapeutic molecules.
The objective is to design and develop a histamine h3 receptor inverse agonist as a novel type of drug for use in the treatment of alzheimer's disease, obesity and/or epilepsy.
Propionic acid bacteria (pab) are applied, together with other dairy bacteria, for development of a swiss flavour concentrate and for improvement of ripening of semi-hard cheeses. The focus is on (directing) routes of flavour formation by pab.
Development of a natural component based on clays, diatomite and seaweeds which will replace the current growth promoters and the fight against mycotoxicosis in animal feed.
Extending the capabilities of an innovative needle-free, single use injector to meet full customisation needs, very high volume manufacturing, minimum time to market delays and very high safety levels.
Production of recombinant allergens and secretory iga in the milk of transgenic rabbits. These compounds will be used for clinical trials to assess their efficiency as a treatment for allergies.
Development of new products to replace the subtherapeutic use of antibiotics and alternatives to the coccidiostatics currently used in farm livestock food.